Our Mission...
is to improve the quality of health service delivery and reduce the burden of disease and disability in the United States and elsewhere by carrying out broadly based research and education activities involving the translation of innovative medical research into practice






Bdolah Y, Palomaki GE, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA: Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol, 194:239-245, 2006.

Canick JA, Lambert-Messerlian G, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D’Alton ME for the First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium. Comparison of serum markers in first-trimester Down syndrome screening. Obstet Gynecol, 108:1192-1199, 2006.

Craig WY, Haddow JE, Palomaki GE, Kelley RI, Kratz LE, Shackleton CHL, Marcos J, Tint GS, Roberson M, MacRae AR, Nowaczyk MJ, Kloza EM, Irons MB: Identifying Smith-Lemli-Optiz syndrome in conjunction with prenatal screening for Down’s syndrome. Prenat Diagn, 26:842-849, 2006.

Haddow JE, Palomaki GE, McClain MR: Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol, 107:205-206, 2006.

Haddow JE, McClain MR, Palomaki GE, Kloza EM, Williams J: Screening for thyroid disorders during pregnancy: Results of a survey in Maine. Am J Obstet Gynecol , 194:471-474, 2006.

Kavsak PA, MacRae AR, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, Yerna MJ, Jaffe AS: The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of myocardial infarction. Am Heart J , 152:118-125, 2006.

Kavsak PA, MacRae AR, Palomaki GE, Newman AM, Ko DT, Lustig V, Tu JV, Jaffe AS: Health outcomes categorized by current and previous definitions of acute myocardial infarction in an unselected cohort of tropin-naive emergency department patients. Clin Chem, 52:2028-2035, 2006.

Lambert-Messerlian GM, Eklund EE, Malone FD, Palomaki GE, Canick JA, D’Alton ME: Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn, 26:17-21, 2006.

MacRae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, Yerna MJ, Jaffe AS: Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin Chem, 52:812-818, 2006.

Palomaki GE, Wright DE, Summers AM, Neveux LM, Meier C, O'Donnell A, Huang T, Knight GJ, Haddow JE: Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: A validation study. Prenat Diagn, 26:730-739, 2006.

Palomaki GE, Knight GJ, Neveux LM, Haddow JE, Pandian R: First-trimester Down syndrome screening (Response to Hallahan). Clin Chem, 52:161, 2006.

Palomaki GE, Steinort K, Knight GJ, Haddow JE: Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. Obstet Gynecol, 107:367-375, 2006.

Palomaki GE, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE: Screen positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a cohort of 21- to 55-year-old women. Genet Med, 8:161-168, 2006.